图书馆主页
数据库简介
最新动态
联系我们



返回首页


 刊名字顺( Alphabetical List of Journals):

  A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL


  检 索:         高级检索

期刊名称:CYTOKINE & GROWTH FACTOR REVIEWS

ISSN:1359-6101
出版频率:Bi-monthly
出版社:ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB
  出版社网址:http://www.elsevier.com
期刊网址:http://www.elsevier.com/wps/find/journaldescription.cws_home/868/description#description
影响因子:7.638
主题范畴:BIOCHEMISTRY & MOLECULAR BIOLOGY;    CELL BIOLOGY

期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)   



About the journal

 Cytokine & Growth Factor Reviews

Cytokine & Growth Factor Reviews publishes thought-provoking articles (critical reviews, state-of-the-art reviews, letters to the editor, meeting reviews) devoted to important advances in the rapidly changing fields of growth factor and cytokine research. Major emphasis is placed on the multidisciplinary significance of cytokines and growth factors in areas as diverse as signal transduction, cell growth and differentiation, embryonic development, immunology, tumorigenesis and clinical medicine.


Instructions to Authors

Guide for Authors



Articles published in Cytokine & Growth Factor Reviews are either written in response to an invitation from the Editor or are submitted to the Editor as unsolicited manuscripts.

Unsolicited manuscripts are welcome and authors who wish to contribute a Survey, Mini Review or Perspective article are encouraged to send a brief outline of the proposed article to the Editor at the address below.

Professor John Hiscott
Molecular Oncology Group
Lady Davis Institute for Medical Research
Jewish General Hospital
3755 Cote. St. Catherine
Montreal,H3T 1E2
Canada
Tel: (+1) 514 340 8222 Ext. 5265
Fax: (+1) 514 340 7576
Email: john.hiscott@mcgill.ca

The Editor will then promptly advise the potential authors whether the content of the proposed article is suitable for publication in Cytokine & Growth Factor Reviews. Acceptance of all submitted manuscripts is at the discretion of the Editors. Authors will receive a free copy of the issue in which they published and twenty-five free offprints. At the end of the year, Elsevier will also offer a US$1000 prize to the corresponding authors of the top three most-downloaded Cytokine & Growth Factor Reviews articles published in that calendar year from the ScienceDirect website (External link http://www.sciencedirect.com/).

All manuscripts should be written in a style suitable for a wide audience of scientists interested in cytokines and growth factors. The Editors encourage the use of schematic diagrams and other illustrations (in colour, where essential) that help convey the major points covered in the article.

Conflict of interest statement

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work, all within 3 years of beginning the work submitted. If there are no conflicts of interest, authors should state that there are none.

The following types of articles are published:

SURVEYS are comprehensive (though not encyclopaedic) reviews, usually 10-15 journal pages long. A typical Survey will consist of approximately 6,000-8,000 words of text, 5-8 figures or tables, and references (not to exceed approximately 150).

MINI REVIEWS are shorter reviews of topics that may be controversial or unresolved, usually 6-10 journal pages long. A typical Mini Review will contain approximately 4,000-6,000 words of text, 2-5 figures or tables, and references (should not exceed 100).

PERSPECTIVES are approximately 3-6 journal pages long and are usually devoted to meeting reports, but may also convey personal viewpoints on selected topics.

MEETING REPORTS are approximately 2-5 journal pages long. Meeting Reports contain a brief summary paragraph followed by the main text of the report. Meeting Reports should be submitted in both hard copy and disk format using the guidelines outlined in the "Manuscript Submission" section of this Guide for Authors.

LETTERS TO THE EDITOR are devoted to the reactions of readers to articles published in Cytokine & Growth Factor Reviews or to matters of general interest to the cytokine and growth factor community. Readers who wish to have their views considered for publication in this section should send brief communications (one printed page or less) to one of the two Editors. The Editors will decide whether the contribution will be published and may edit or shorten the text. Letters to the Editor should be submitted in both hard copy and disk format using the guidelines outlined in the "Manuscript Submission" section of this Guide for Authors.

The following guidelines should be used by authors in the preparation of Surveys, Mini Reviews and Perspectives as appropriate:

Title. The title should be concise and informative. Author affiliations should include full postal address and telephone, fax and e-mail numbers for each author.

Abstract. Each article should begin with a short abstract (up to a maximum of 120 words) that provides a succinct summary of the review subject matter.

Keywords. Authors should provide up to five relevant keywords with their article.

Table of Contents. Each Survey should include a Table of Contents, which should list all headings and subheadings, numbered accordingly to the scheme followed in the main text (see below).

Main Text. The main text of the article should have one or two introductory paragraphs and then include suitable headings and sub-headings to highlight major themes. Each heading and sub-heading should have a short descriptive title. The preferred numbering scheme is: 1., 1.1., 1.1.1., 1.1.2., 1.1.3., etc. All headings should by typed on a separate line, not run into the paragraph.

DNA sequences and GenBank Accession numbers. Many Elsevier journals cite "gene accession numbers" in their running text and footnotes. Gene accession numbers refer to genes or DNA sequences about which further information can be found in the databases at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine. Elsevier authors wishing to enable other scientists to use the accession numbers cited in their papers via links to these sources, should type this information in the following manner: For each and every accession number cited in an article, authors should type the accession number in bold, underlined text . Letters in the accession number should always be capitalised (see example below). This combination of letters and format will enable Elsevier's typesetters to recognise the relevant texts as accession numbers and add the required link to GenBank's sequences.

Example: "GenBank accession nos. AI631510 , AI631511 , AI632198 , and BF223228 ), a B-cell tumor from a chronic lymphatic leukemia (GenBank accession no. BE675048 ), and a T-cell lymphoma (GenBank accession no. AA361117 )".

Authors are encouraged to check accession numbers used very carefully. An error in a letter or number can result in a dead link. In the final version of the printed article, the accession number text will not appear bold or underlined. In the final version of the electronic copy, the accession number text will be linked to the appropriate source in the NCBI databases enabling readers to go directly to that source from the article.

Figures. All figures should be original glossy photographs or professional drawings (high quality computer generated artwork is acceptable). Please do not frame the figures. Mark the back of each figure within its number and the first author's name, and indicate the top of the figure. Figures are generally reduced to 172 mm width or less when published. Type the legends in order on a separate page; limit the legend to 40 words or less. Cite the figures consecutively in the text. Colour figures are reproduced free of charge, provided that the colour enhances the clarity of the data presented.

Tables. Type tables on separate pages with a title. Avoid white space in the table by using footnotes, and ensure all symbols or abbreviations are explained. Cite tables consecutively in the text.

Abbreviations. Widely recognised abbreviations are acceptable but all others should be explained at first mention in the summary and text.

References. List references on a new sheet and number them consecutively in square brackets in the text. "Unpublished data" and "Personal communications" are not allowed. As an alternative, say in the text, for example, "(data not shown)" or "(Dr F G Tomlin, Karolinska Institute)". Accepted but unpublished papers (but not submitted manuscripts) can be referenced as "in press".

The format of references should be that of the Vancouver guidelines (J Am Med Assoc 1997;277:927-34). Include:

The names of all the authors when six or fewer, followed by their initials. To indicate additional authors, simply use "et al".
The title of the article or chapter.
The journal name abbreviated as in Index Medicus, the year and volume, and the first and last pages.
For a book, the names of any editors (as for authors), the city and name of the publisher, and the year and pages.
Examples for an article in a journal (1) or book (2) or for a book (3) would be:

1. Jiang FN, Liu DJ, Neyndorff H, Chester M, Jiang SY, Luy JG. Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J Natl Cancer Inst 1991;83:1218-25.

2. Gullick WJ, Venter DJ. The c-erbB2 and its expression in human tumours. In: Waxman J, Sikora K, editors. The Molecular Biology of Cancer. Oxford: Blackwell Scientific Publications; 1989, p. 38-53.

3. Lumley JSP, Green CJ, Lear P, Angell-James JE. Essentials of Experimental Surgery. London: Butterworths; 1990.

Supplementary Data. Elsevier now accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier web products, including ScienceDirect: External link http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit External link http://www.elsevier.com/wps/find/authors.authors/authorartworkinstructions.

Files can be stored on 3.5 inch diskette, ZIP-disk or CD (either MS-DOS or Macintosh).

Manuscript Submission. One original and two additional copies of the manuscript and illustrations should be submitted to one of the Editors in double-spaced typing with ample margins. Authors should designate in the text where tables and figures should appear, but the tables and figures should be collected after the references. A disk should be supplied with the manuscript; the disk file should exactly match the printed manuscript. Disks should preferably be IBM-PC compatible, using Word-Perfect or Microsoft Word word processing programmes or alternatively ASCII text files in IBM-PC/MS-DOS format, although other systems (e.g. Macintosh) are acceptable. Please label the disk with your name, the software and hardware used, the journal title and the name of the file to be processed.

Biographical Information and Photographs of Authors. A concise summary of biographical information of the author(s) should be supplied, describing academic record, postdoctoral and other positions, current research interests and any other directly relevant information (positions on scientific societies, awards etc.). The total length should be 100-200 words. The biographical details of the principal author(s) may be more detailed than that of the other co-author(s) if appropriate.

Black and white individual passport size photographs (approximately 6 x 4 cm) or, if appropriate, group photographs of the author(s) should be attached.

Copyright. Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the Publisher.

Upon acceptance of an article, authors will be asked to transfer copyright (for more information on copyright see External link http://www.elsevier.com/wps/find/supportfaq.cws_home/copyright). This transfer will ensure the widest possible dissemination of information. A letter will be sent to the corresponding author confirming receipt of the manuscript. A form facilitating transfer of copyright will be provided.

If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier's Rights Department, Philadelphia, PA, USA; phone: (+1) 215 238 7869, fax: (+1) 215 238 2239, e-mail: healthpermissions@elsevier.com. Requests may also be completed on-line via the Elsevier homepage: External link http://www.elsevier.com/locate/permissions.

Proof Corrections. Elsevier will do everything possible to get your article corrected and published as quickly as possible. Therefore it is important to ensure that all of your corrections are returned to us in one all-inclusive e-mail or fax. Subsequent additional corrections will not be possible, so please ensure that your first communication is complete.

Editorial Board
Editors:
M.B. Sporn, Professor of Pharmacology, Dartmouth Medical
School, Hanover, NH 03755-3835, USA
J.T. Vilcek, Professor of Microbiology, NYU Medical Center, 550
First Avenue, New York, NY 10016-6402, USA
Editorial Board:
C. Basilico, NYU Medical Center, New York, NY, USA
M.V. Chao, Cornell University, New York, NY, USA
S.J. Durum, National Cancer Institute, Frederick, MD, USA
M. Feldmann, The Mathilda & Terence Kennedy Institute of
Rheumatology, London, UK
M.J. Fenton, University of Maryland School of Medicine, College
Park, MD, USA
C.-H. Heldin, Ludwig Institute Cancer Research, Uppsala, Sweden
D.J. Hilton, The Walter & Eliza Hall Institute for Medical Research,
Melbourne, Victoria, Australia
T. Hirano, Osaka University Medical School, Osaka, Japan
J. Hiscott, McGill University, Montreal, Quebec, Canada
M. Klagsbrun, Harvard Medical School, Boston, MA, USA
M. Krönke, Institut für Immunologie, Kiel, Germany
D. Le Roith, National Institutes of Health, Bethesda, MD, USA
W.J. Leonard, National Institutes of Health, Bethesda, MD, USA
D.E. Levy, NYU School of Medicine, New York, USA
2
K. Miyazono, Cancer Institute of the Japanese Foundation for
Cancer Research, Kami-ikebukuro, Japan
C.F. Nathan, Cornell University Medical College, New York, NY,
USA
J.J. Oppenheim, National Cancer Institute, Frederick, MD, USA
R.W. Padgett, Rutgers University, Piscataway, NJ, USA
S. Pestka, UMDNJ-Robert Wood Johnson Medical School,
Piscataway, NJ, USA
K. Pfizenmaier, Institute für Zellbiologie und Immunologie, Stuttgart,
Germany
H.A. Reddi, University of California Davis Medical Center,
Sacramento, CA, USA
A.B. Roberts, National Cancer Institute, Bethesda, MD, USA
G. Rodan, Merck & Co. Inc., West Point, PA, USA
J. Schlessinger, New York University Medical Center, NY, USA
M.D. Schneider, Baylor College of Medicine, Houston, TX, USA
T. Taniguchi, University of Tokyo, Tokyo, Japan
G. Trinchieri, Schering-Plough Lab of Immunological Research,
Dardilly, France
J. Van Damme, Katholieke Universiteit, Rega Instituut, Leuven,
Belgium
S. Wahl, National Institutes of Health, Bethesda, MD, USA
D. Wallach, The Weizmann Institute of Science, Rehovot, Israel
C.F. Ware, La Jolla Institute for Allergy & Immunology, San Diego,
CA, USA
Editorial Board
c1359-6101.pdf


 返回页首 


邮编:430072   地址:中国武汉珞珈山   电话:027-87682740   管理员Email:
Copyright © 2005-2006 武汉大学图书馆版权所有